Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Dry skin, Dysphonia, Erythema, Eye pruritus
Clinical narrative: Burning on my face and neck; dryness; local itching/ generalized itching; red eyes; itchy eyes; prickling/ tingling sensation; hoarseness; local rash; spot on my forehead and neck; hypersensitivity reaction; Redness on face and neck,redness,face began to have splotchy red places,local redness; This spontaneous case was reported by a consumer and describes the occurrence of RASH MACULAR (spot on my forehead and neck), HYPERSENSITIVITY (hypersensitivity reaction), ERYTHEMA (Redness on face and neck,redness,face began to have splotchy red places,local redness), BURNING SENSATION (Burning on my face and neck) and DRY SKIN (dryness) in a 65-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 031A21A and 002A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.  Previously administered products included for Infection: doxycycline in May 1985. Past adverse reactions to the above products included Redness generalised with doxycycline.   On 04-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 04-Apr-2021, the patient experienced RASH MACULAR (spot on my forehead and neck), HYPERSENSITIVITY (hypersensitivity reaction), ERYTHEMA (Redness on face and neck,redness,face began to have splotchy red places,local redness), DRY SKIN (dryness), PRURITUS (local itching/ generalized itching), OCULAR HYPERAEMIA (red eyes), EYE PRURITUS (itchy eyes), PARAESTHESIA (prickling/ tingling sensation), DYSPHONIA (hoarseness) and RASH (local rash). On an unknown date, the patient experienced BURNING SENSATION (Burning on my face and neck). The patient was treated with HYDROCORTISONE ongoing from 06-Apr-2021 at an unspecified dose and frequency and TIRBANIBULIN (KLISYRI) at an unspecified dose and frequency. At the time of the report, RASH MACULAR (spot on my forehead and neck) and HYPERSENSITIVITY (hypersensitivity reaction) had not resolved and ERYTHEMA (Redness on face and neck,redness,face began to have splotchy red places,local redness), BURNING SENSATION (Burning on my face and neck), DRY SKIN (dryness), PRURITUS (local itching/ generalized itching), OCULAR HYPERAEMIA (red eyes), EYE PRURITUS (itchy eyes), PARAESTHESIA (prickling/ tingling sensation), DYSPHONIA (hoarseness) and RASH (local rash) outcome was unknown.            Concomitant medication of the patient was not reported.   Most recent FOLLOW-UP information incorporated above includes: On 04-Aug-2021: Patient information, past medical history, suspect drug dosage details, facility information were updated. New events of rash macular, hypersensitivity, dry skin, pruritus, ocular hyperaemia, eye pruritus, paranesthesia, dysphonia and rash were added. On 04-Aug-2021: Follow-up information included no new information. On 04-Aug-2021: Follow-up information included no new information.